Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Albemarle

Valuation and fundamentals always matter, driving 97% of long-term stock returns. The market is capable of incredible "fat pitch" discounts and also creates insane bubbles. Albemarle Corporation is the world's leading lithium miner and is 65% undervalued, trading at less than 6X earnings, the lowest P/E in over 20 years.

Albemarle Vs. Eli Lilly: 1 Potentially Set To Soar And 1 Bubble Stock To Ignore

Pfizer

Roche Holding AG

Roche spent $7.1 billion on a company, primarily because of an IBD therapy. Pfizer just got approval for a pill to treat ulcerative colitis.

Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?

Eli Lilly and Co (NYSE:LLY) is scheduled to report earnings before the market opens on Thursday, with analysts expecting revenue growth but an earnings decline.  The drugmaker is expected to post a third-quarter adjusted loss of $0.15 per share on revenue of $8.95 billion, compared to earnings of $1.61 per share on revenue of $6.94 billion a year earlier.

Eli Lilly diabetes drug Mounjaro will be in focus when the drugmaker reports earnings next week

Novo Nordisk

West Pharmaceutical Services

Soaring demand for obesity drugs was in the spotlight at the world's largest trade show for the pharmaceutical services industry this week, as it fuels a boom for firms that fill and assemble the self-injection pens.

Weight-loss drugs in spotlight as pharma services firms rush to snap up business

Eli Lilly and Co (NYSE:LLY) has announced that its Omvoh drug has been approved by the US Food and Drug Administration to treat types of inflammatory bowel disease. Following a third-phase 12-week clinical trial, in which Omvoh prompted responses in 65% of patients and remission in 24%, Eli Lilly announced the approval on Thursday.

Eli Lilly bowel disease drug approved in US

Eli Lilly and Company said on Thursday that the U.S. health regulator had approved its drug for treating adults with moderately to severely active ulcerative colitis, a type of chronic inflammatory bowel disease.

Eli Lilly's bowel disease drug gets US FDA's approval in adults

Omvoh achieved primary and key secondary endpoints, including sustained clinical remission in pivotal trials Omvoh delivered significant improvement in bowel urgency, reported by people with UC as one of the most disruptive symptoms Lilly's first approved treatment for a type of inflammatory bowel disease INDIANAPOLIS , Oct. 26, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh™ (mirikizumab-mrkz) infusion (300 mg/15 mL)/injection (100 mg/mL), the first and only interleukin-23p19 (IL-23p19) antagonist for the treatment of moderately to severely active ulcerative colitis (UC) in adults. Marking a significant milestone, Omvoh is the only UC treatment that selectively targets the p19 subunit of IL-23, which plays a role in inflammation related to UC.

FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Eli Lilly (LLY) Q3 Earnings Expected to Decline

INDIANAPOLIS , Oct. 26, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the UBS Biopharma Conference on Nov. 8, 2023. Patrik Jonsson, executive vice president; president, Lilly Immunology; president, Lilly USA; and chief customer officer, will participate in a fireside chat at 3 p.m.

Lilly to Participate in UBS Biopharma Conference 2023

Eli Lilly has the potential to be a huge name in weight loss by the end of the decade. Tesla has significant potential in the electric vehicle market, but it could face a lot of competition.

Will Eli Lilly Stock Be Worth More Than Tesla Stock by 2030?

RICHMOND, Calif.--(BUSINESS WIRE)-- #aging--BioAge Labs, Inc., (“BioAge”), a clinical-stage biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced plans to initiate a Phase 2 trial of its oral apelin receptor agonist BGE-105 (azelaprag) co-administered with the GLP-1/GIP receptor agonist tirzepatide for treatment of obesity. BioAge plans to initiate the trial in mid-2024. Chorus (link), an operationally independent clinic.

BioAge Labs Announces Plans for Phase 2 Trial of First-in-Class Apelin Receptor Agonist BGE-105/Azelaprag Co-Administered With Tirzepatide for Treatment of Obesity, in Collaboration With Lilly's Chorus Organization

DraftKings

Oracle

Pioneer Natural Resources

Here is an update on our Inverse Jim Cramer strategy by taking a look at the results of his top stock picks for the quarter ending in September. This quarter, we collected and analyzed more than 400 of Cramer's stock picks. Cramer discussed stocks like Eli Lilly and Company, DraftKings, and Oracle the most in Q3.

Inverse Jim Cramer Strategy - Q3 2023 Update

Akamai Technologies

Allstate

Amgen

Arista Networks

Axon Enterprise

Cboe Global Markets

Constellation Energy Corp

Diamondback Energy

Humana

McKesson

Marathon Petroleum

NRG Energy

Progressive

Don't assume that all S&P 500 stocks are struggling. A small group are actually thriving, thank you.

Investors Scurry To Buy 14 Soaring Stocks As Market Sells Off

Avantor Inc.

Catalent

Danaher

DexCom

Inspire Medical Systems Inc

Coca-Cola

PepsiCo

Insulet

Repligen

Thermo Fisher Scientific

Walmart

Citing Vanda Research, the Wall Street Journal reports that the average individual-investor stock portfolio is up 150% since the start of 2014, versus around 140% for the S&P 500's SPX during the same period.

The weight-loss drugs are coming for these companies — but here's why Coke, others, may be spared, says JPMorgan

Combination of Elektrofi's ultra-high concentration microparticle suspension technology platform and Lilly's therapeutic expertise could expand new frontiers in patient-centric drug delivery innovation Combination of Elektrofi's ultra-high concentration microparticle suspension technology platform and Lilly's therapeutic expertise could expand new frontiers in patient-centric drug delivery innovation

Elektrofi and Lilly Enter Multi-Target Research Collaboration and License Agreement

Citi notched its estimate for incretin drug sales to $71 billion by 2035, up from its prior estimate of $55 billion. That view seems conservative.

Wall Street hikes forecasts for anti-obesity drug sales to $100 billion and beyond — A look at the numbers

Eli Lilly's diabetes drug Mounjaro is expected to be approved to treat obesity in the near future. It could drive sales for more than a decade.

Eli Lilly Is Waiting for Obesity-Drug Approval. Here's How Much It Could Be Worth.

Vertex Pharmaceuticals

Eli Lilly's growth is just getting started. Novo Nordisk shows no signs of slowing down, thanks to soaring sales of Ozempic and Wegovy.

3 Unstoppable Stocks to Buy Sooner Rather Than Later

-  In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection ( RET) fusion-positive non-small cell lung cancer (NSCLC) - In the Phase 3 LIBRETTO-531 study, Retevmo provided a 72% improvement in PFS compared to cabozantinib or vandetanib in patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) INDIANAPOLIS , Oct. 21, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from both the LIBRETTO-431 Phase 3 study, which evaluated Retevmo® (selpercatinib) versus platinum-based chemotherapy — with or without pembrolizumab — as an initial treatment for patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), and the LIBRETTO-531 Phase 3 study, which evaluated Retevmo versus multikinase inhibitors (MKIs) in patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC). In both clinical studies, results were based on pre-specified interim efficacy analyses conducted by independent data monitoring committees (IDMC).

Lilly's Retevmo® (selpercatinib) Phase 3 Results in RET Fusion-Positive Non-Small Cell Lung Cancer and RET-Mutant Medullary Thyroid Cancer Both Published in The New England Journal of Medicine and Presented in a Presidential Symposium at ESMO Congress 202

Get ready for Ozem-kids! The pharmaceutical companies behind Ozempic, Mounjaro and Wegovy — which have exploded in popularity with adults looking to lose weight — are testing whether the drugs are safe for children.

Pharma firms testing weight loss drugs for kids amid Ozempic craze

Eli Lilly and Co (NYSE:LLY) is planning a trial of its diabetes drug Mounjaro in patients with obesity as young as six years old according to a Bloomberg report Friday citing a person familiar with the matter. The company is already carrying out a Phase 3 trial of the drug in children as young as 10 years old and teenagers with type 2 diabetes.

Eli Lilly planning diabetes drug trial for children six years and older: report

INDIANAPOLIS , Oct. 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2023 financial results on Thursday, Nov. 2, 2023. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.

Lilly Confirms Date and Conference Call for Third-Quarter 2023 Financial Results Announcement

Impact of two years of adjuvant Verzenio treatment is observed well beyond the treatment period, reducing the risk of long-term recurrence by 32% and improving invasive disease-free survival by 7.6% at 5 years These data reinforce two years of Verzenio plus endocrine therapy as the standard of care for these patients in this curative setting Use of Verzenio as a treatment option in this setting is supported by an NCCN® Category 1 designation INDIANAPOLIS , Oct. 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced five-year outcomes from a pre-planned analysis of the Phase 3 monarchE study evaluating two years of adjuvant Verzenio® (abemaciclib) in combination with endocrine therapy (ET) compared with ET alone in patients with HR+, HER2-, node-positive early breast cancer (EBC) at a high risk of recurrence. These data were shared in a late-breaking presentation at the 2023 European Society for Medical Oncology (ESMO) Congress.

Landmark 5-Year monarchE Outcome Data Demonstrate Verzenio® (abemaciclib)'s Long-Term Impact on Cancer Recurrence in High-Risk Early Breast Cancer

First readout of two-year data from long-term extension study INDIANAPOLIS , Oct. 20, 2023 /PRNewswire/ -- Patients with moderate-to-severe atopic dermatitis who continued treatment with investigational lebrikizumab for up to two years experienced sustained skin clearance, itch relief and reduced disease severity with monthly maintenance dosing as demonstrated in the ADjoin long-term extension study from Eli Lilly and Company (NYSE: LLY). Results from ADjoin will be presented at the 43rd Annual Fall Clinical Dermatology Conference happening from October 19-22 in Las Vegas, Nevada.1  "Lebrikizumab, administered with a once-monthly dose following an induction phase, demonstrated efficacy for patients with moderate-to-severe atopic dermatitis, offering sustained relief from some of the most distressing signs and symptoms of the disease," said Emma Guttman-Yassky, M.D.

Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost clear skin with Lilly's lebrikizumab monthly maintenance dosing at two years

Eli Lilly is planning a clinical trial of its diabetes drug Mounjaro in patients six years and older who have obesity, Bloomberg News reported on Friday, citing a person familiar with the matter.

News for Eli Lilly Stock (LLY)